Please login to the form below

Crysvita

This page shows the latest Crysvita news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Crystiva for rare bone disease

Tom Stratford, CEO, Kyowa Kirin International said: It is a major development that NICE has recommended Crysvita for routine use among children and young people with XLH in England and Wales. ... Crysvita targets this pathway by blocking the activity of

Latest news

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).
NICE set to reject Kyowa Kirin’s Crysvita for XLH

is set to receive a NICE rejection for its rare disease therapy Crysvita (burosumab). ... Crysvita’s annual pricing is conditional on the patient’s weight but has an upper estimated price of an eye watering £388, 960 a year for a 17-year-old
Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Ultragenyx’s FDA approval was for Crysvita (burosumab), which has become the first approved drug for adults and children ages one year and older with X-linked

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Editorial Manager - MedComms: DOE

Senior Editorial Assistant – Greater Manchester: DOE

Business Director: Competitive Salary Offered

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Account Director: Competitive Salary Offered

Principal Health Economist - North-West: Negotiable

Medical Writer: Salary TBC

Account Manager / Account Director: Competative

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Healthcare Communications Account Directors x 2: Salary TBC

Associate Director: £75, 000-90, 000

Account Manager: Negotiable

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Systematic Reviewer - Oxford: Negotiable

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Experienced Medical Writers: Competitive Salary and Benefits

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Medical (Scientific) Director: £120, 000 benefits

Account Executive/ Senior Account Executive: competitive Salary Offfered

Subscribe to our email news alerts

PMHub

Add my company

Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...